Finally, our analysis of clinical data available from large RNA expression cohorts suggests that high baseline SNAT2 expression correlates with poor survival in patients with breast cancer and with reduced recurrence-free survival in ER+ endocrine-treated breast cancer patients, specifically in the luminal B subtype (ER+ subtype). Here, SLC38A2 is linked to breast carcinoma.